Related references
Note: Only part of the references are listed.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)
Borja Ibanez et al.
EUROPEAN HEART JOURNAL (2018)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Marco Valgimigli et al.
EUROPEAN HEART JOURNAL (2018)
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial
Marco Valgimigli et al.
EUROPEAN HEART JOURNAL (2017)
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study
Thomas Cuisset et al.
EUROPEAN HEART JOURNAL (2017)
Randomized Comparison of Oral P2Y12-Receptor Inhibitor Loading Strategies for TransitioningFromCangrelor The ExcelsiorLOAD2 Trial
Willibald Hochholzer et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2017)
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
E. Magnus Ohman et al.
LANCET (2017)
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial
Dirk Sibbing et al.
LANCET (2017)
Single or dual antiplatelet therapy after PCI
Yosuke Miyazaki et al.
NATURE REVIEWS CARDIOLOGY (2017)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
J. W. Eikelboom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Acute Myocardial Infarction
Jeffrey L. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial
Dirk Sibbing et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Antithrombotic therapy for acute coronary syndrome: Past, present and future
Dirk Sibbing et al.
THROMBOSIS AND HAEMOSTASIS (2017)
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
Marco Roffi et al.
EUROPEAN HEART JOURNAL (2016)
Switching P2Y(12)-receptor inhibitors in patients with coronary artery disease
Fabiana Rollini et al.
NATURE REVIEWS CARDIOLOGY (2016)
Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention Multicenter Randomized PRAGUE-18 Study
Zuzana Motovska et al.
CIRCULATION (2016)
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor Results of the Prospective, Randomized SWAP-3 Study
Francesco Franchi et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2016)
Smoking and Clopidogrel Response Revisited Hemoglobin Levels Explaining the Smoker's Paradox
Dirk Sibbing et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2016)
CYP2C19 in ACS Patients Could Genotyping Have a Role in Medically Managed Patients or Beyond?
Dirk Sibbing et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack
S. Claiborne Johnston et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Platelet Function Testing in Patients on Antiplatelet Medications
Lisa Gross et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2016)
Pharmacodynamic effects during the transition between cangrelor and prasugrel
David J. Schneider et al.
CORONARY ARTERY DISEASE (2015)
Pharmacodynamic Effects When Clopidogrel is Given Before Cangrelor Discontinuation
David J. Schneider et al.
JOURNAL OF INTERVENTIONAL CARDIOLOGY (2015)
Novel antiplatelet agents in acute coronary syndrome
Francesco Franchi et al.
NATURE REVIEWS CARDIOLOGY (2015)
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study
Thomas O. Bergmeijer et al.
AMERICAN HEART JOURNAL (2014)
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention
Daniel Aradi et al.
EUROPEAN HEART JOURNAL (2014)
Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor-Mediated Signaling in Prasugrel-Treated Patients
Fabiana Rollini et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2014)
Pharmacodynamic Effects During the Transition Between Cangrelor and Ticagrelor
David J. Schneider et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2014)
Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease Results of the SWAP-2 Study (Switching Anti Platelet-2)
Dominick J. Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI
Glenn N. Levine et al.
NATURE REVIEWS CARDIOLOGY (2014)
Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy-Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial
Stefanie Schulz et al.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2014)
Response Variability to P2Y12 Receptor Inhibitors Expectations and Reality
Jolanta M. Siller-Matula et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2013)
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Drug-Eluting Coronary-Artery Stents
Giulio G. Stefanini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Increased clopidogrel response is associated with ABCC3 expression: A pilot study
Andre Ducati Luchessi et al.
CLINICA CHIMICA ACTA (2012)
Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery A Randomized Controlled Trial
Dominick J. Angiolillo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model
J. J. J. van Giezen et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2012)
Recovery of Platelet Function After Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Patients With Stable Coronary Disease The Recovery Trial
Matthew J. Price et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting
Nikolaus Sarafoff et al.
AMERICAN HEART JOURNAL (2011)
Identifying Patients at Risk for Premature Discontinuation of Thienopyridine After Coronary Stent Implantation
Alexandre S. Quadros et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Ticagrelor
Michael A. Gaglia et al.
CIRCULATION (2011)
Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement
Dietmar Trenk et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2011)
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting
Dirk Sibbing et al.
EUROPEAN HEART JOURNAL (2011)
Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis
Guillaume Cayla et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated With Percutaneous Coronary Intervention Relationship With Gene Polymorphisms and Clinical Outcome
Gianluca Campo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
Dominick J. Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Paraoxonase-1 is a major determinant of clopidogrel efficacy
Heleen J. Bouman et al.
NATURE MEDICINE (2011)
Cytochrome P450 2C19☆2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis
F. Sofi et al.
PHARMACOGENOMICS JOURNAL (2011)
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies The RESPOND Study
Paul A. Gurbel et al.
CIRCULATION (2010)
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
Dirk Sibbing et al.
CIRCULATION (2010)
Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel
Dirk Sibbing et al.
EUROPEAN HEART JOURNAL (2010)
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study
Ankie M. Harmsze et al.
EUROPEAN HEART JOURNAL (2010)
Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition
Thomas Gremmel et al.
HEART (2010)
Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day Results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) Study
Young-Hoon Jeong et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2010)
Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI A Meta-analysis
Jessica L. Mega et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans
Nagy A. Farid et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes Results of the SWAP (SWitching Anti Platelet) Study
Dominick J. Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy
Robert F. Storey et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent Placement
Willibald Hochholzer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
Jessica L. Mega et al.
LANCET (2010)
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
Lars Wallentin et al.
LANCET (2010)
Antiplatelet therapies for the treatment of cardiovascular disease
Alan D. Michelson
NATURE REVIEWS DRUG DISCOVERY (2010)
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
Guillaume Pare et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease The ONSET/OFFSET Study
Paul A. Gurbel et al.
CIRCULATION (2009)
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Dirk Sibbing et al.
EUROPEAN HEART JOURNAL (2009)
P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
Lars Wallentin
EUROPEAN HEART JOURNAL (2009)
Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation
J. J. J. van Giezen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
Jean-Philippe Collet et al.
LANCET (2009)
Intravenous Platelet Blockade with Cangrelor during PCI.
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Platelet Inhibition with Cangrelor in Patients Undergoing PCI.
Robert A. Harrington et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events.
Tabassome Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects
Ying G. Li et al.
PLATELETS (2009)
Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response
Thomas Cuisset et al.
THROMBOSIS RESEARCH (2009)
Clinical overview of promising nonthienopyridine antiplatelet agents
Dominick J. Angiolillo et al.
AMERICAN HEART JOURNAL (2008)
Pharmacology of emerging novel platelet inhibitors
Dominick J. Angiolillo et al.
AMERICAN HEART JOURNAL (2008)
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin
Martine Gilard et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
The association of cigarette smoking with enhanced platelet inhibition by clopidogrel
Kevin P. Bliden et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect
Steven R. Steinhubl et al.
THROMBOSIS RESEARCH (2008)
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention - The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
Stephen D. Wiviott et al.
CIRCULATION (2007)
Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile
Joseph A. Jakubowski et al.
CARDIOVASCULAR DRUG REVIEWS (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Safety, tolerability, and initial efficacy of AZD6140, the first reversivle oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial
Christopher P. Cannon et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
Christopher D. Payne et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction:: Results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial
Adam B. Greenbaum et al.
AMERICAN HEART JOURNAL (2007)
Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of Clopidogrel before percutaneous coronary intervention
Dirk Sibbing et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
The disposition of prasugrel, a novel thienopyridine, in humans
Nagy A. Farid et al.
DRUG METABOLISM AND DISPOSITION (2007)
Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention
Ehtisham Mahmud et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
John T. Brandt et al.
AMERICAN HEART JOURNAL (2007)
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes - The ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial
Gilles Montalescot et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Onset and offset of platelet inhibition after high-dose Clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers
Matthew J. Price et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel
Dominick J. Angiolillo et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
T Jernberg et al.
EUROPEAN HEART JOURNAL (2006)
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:: a double-blind comparison to clopidogrel with aspirin
S Husted et al.
EUROPEAN HEART JOURNAL (2006)
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
JLF Rehmel et al.
DRUG METABOLISM AND DISPOSITION (2006)
Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel -: Results of the ISAR-CHOICE (Intracoronary stenting and antithrombotic regimen:: Choose between 3 high oral doses for immediate clopidogrel effect) trial
N von Beckerath et al.
CIRCULATION (2005)
Randomized comparison of Prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention -: Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial
SD Wiviott et al.
CIRCULATION (2005)
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
WC Lau et al.
CIRCULATION (2004)
Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease
RF Storey et al.
PLATELETS (2002)
Effects of P2Y1 and P2Y12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood
RF Storey et al.
PLATELETS (2001)
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement
I Muller et al.
HEART (2001)
Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting - The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)
ME Bertrand et al.
CIRCULATION (2000)
A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents
C Müller et al.
CIRCULATION (2000)
Share Paper
